Target Exclusivity. ISIS hereby agrees that, until such time as the approval of the first marketing application for a Compound in a Major Market pursuant to this Agreement, ISIS will work exclusively (even as to ISIS itself) with MERCK with regard to any and all activities for the research, discovery, development and/or commercialization of antisense compounds and products that target the genetic sequence of PTP-1B.
Appears in 2 contracts
Sources: Development and License Agreement (Isis Pharmaceuticals Inc), Development and License Agreement (Isis Pharmaceuticals Inc)